Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Preventing metastases by tackling exosomes

Dr Jeff Wrana - University of Toronto, Canada
Preventing metastases by tackling exosomes ( Dr Jeff Wrana - University of Toronto, Canada )
19 Dec 2013

Moving breast cancer stem cell therapies to the clinic

Dr Max Wicha - University of Michigan, Ann Arbor, USA
Moving breast cancer stem cell therapies to the clinic ( Dr Max Wicha - University of Michigan, Ann Arbor, USA )
19 Dec 2013

PIK3CA mutation predicts resistance to anti-HER2 treatment and chemotherapy

Dr Sibylle Loibl - German Breast Cancer Group
PIK3CA mutation predicts resistance to anti-HER2 treatment and chemotherapy ( Dr Sibylle Loibl - German Breast Cancer Group )
19 Dec 2013

Where to next for the elderly with acute myeloid leukaemia?

Dr Uwe Platzbecker - University Hospital Dresden, Germany and Prof Gert Ossenkoppele - VU University Medical Center, Amsterdam, Netherlands
Where to next for the elderly with acute myeloid leukaemia? ( Dr Uwe Platzbecker - University Hospital Dresden, Germany and Prof Gert Ossenkoppele - VU University Medical Center, Amsterdam, Netherlands )
19 Dec 2013

New line of therapy for acute myeloid leukaemia

Dr David Taussig - Barts Cancer Institute, London, UK
New line of therapy for acute myeloid leukaemia ( Dr David  Taussig - Barts Cancer Institute, London, UK )
18 Dec 2013

Encouraging early results with GS-9973 for CLL and NHL

Dr Jeff Sharman- US Oncology, Eugene, Oregon
Encouraging early results with GS-9973 for CLL and NHL ( Dr Jeff Sharman- US Oncology, Eugene, Oregon )
18 Dec 2013

Idelalisib and rituximab for previously treated chronic lymphocytic leukaemia (CLL)

Dr Richard Furman - New York Weill Cornell Medical Center, USA
Idelalisib and rituximab for previously treated chronic lymphocytic leukaemia (CLL) ( Dr Richard Furman - New York Weill Cornell Medical Center, USA )
17 Dec 2013

Treating ALL patients with T cells targeted for CD19

Dr Laurence Cooper - MD Anderson Cancer Center, Houston, USA
Treating ALL patients with T cells targeted for CD19 ( Dr Laurence Cooper - MD Anderson Cancer Center, Houston, USA )
8 Dec 2013

Chimeric antigen receptor produces complete responses and long-term persistence in children and adults relapsed, refractory ALL

Dr. Stephen A. Grupp - University of Pennsylvania, Philadelphia, USA
Chimeric antigen receptor produces complete responses and long-term persistence in children and adults relapsed, refractory ALL ( Dr. Stephen A. Grupp - University of Pennsylvania, Philadelphia, USA )
8 Dec 2013

Long-term functional persistence, B cell aplasia and anti-leukaemia efficacy in refractory B cell malignancies

Dr Michael Kalos - University of Pennsylvania, Philadelphia, USA
Long-term functional persistence, B cell aplasia and anti-leukaemia efficacy in refractory B cell malignancies ( Dr Michael Kalos - University of Pennsylvania, Philadelphia, USA )
8 Dec 2013

T cells engineered with chimeric antigen receptor targeting CD19 produce significant long-term persistence

Dr Stephen A. Grupp - University of Pennsylvania, Philadelphia, USA
T cells engineered with chimeric antigen receptor targeting CD19 produce significant long-term persistence ( Dr Stephen A. Grupp - University of Pennsylvania, Philadelphia, USA )
8 Dec 2013

Removal of alpha/beta T cells and of CD19 B cells in children With acute leukaemia

Dr Alice Bertaina - IRCCS Bambino Gesù Children's Hospital, Rome, Italy
Removal of alpha/beta  T cells and of CD19  B cells in children With acute leukaemia ( Dr Alice Bertaina - IRCCS Bambino Gesù Children's Hospital, Rome, Italy )
8 Dec 2013